Trial reportAntimicrobial agents and chemotherapy1997
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
Trial report in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Interethnic differences in pharmacokinetics of antibacterials.Clinical pharmacokinetics · 2015Pooled it
- Pooled it
- Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Pooled it
- Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections.Clinical pharmacokinetics · 2005Pooled it
- Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India.Antimicrobial agents and chemotherapy · 2018Trial
- Identifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach.British journal of clinical pharmacology · 2016Trial
- Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.Antimicrobial agents and chemotherapy · 2015Trial
- Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.Antimicrobial agents and chemotherapy · 2011Trial
- Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.Antimicrobial agents and chemotherapy · 2011Trial
- Trial
- Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies.Bone marrow transplantation · 2004Trial
- Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.Antimicrobial agents and chemotherapy · 2003Trial
- Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.Clinical pharmacokinetics · 2003Trial
- Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.Antimicrobial agents and chemotherapy · 2001Trial
- Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species.Antimicrobial agents and chemotherapy · 2000Trial
- Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.Antimicrobial agents and chemotherapy · 2000Trial
- A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin.Antimicrobial agents and chemotherapy · 2000Trial
- Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients.Antimicrobial agents and chemotherapy · 1999Trial
- Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.Antimicrobial agents and chemotherapy · 1998Trial
- Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.Antimicrobial agents and chemotherapy · 1997Trial
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmacokinetics of once-daily oral levofloxacin (study A) or intravenous levofloxacin (study B) in 40 healthy male volunteers were investigated in two separate randomized, double-blind, parallel-design, placebo-controlled studies. Levofloxacin at 500 mg or placebo was administered orally or intravenously as a single dose on day 1; daily oral or intravenous dosing resumed on days 4 to 10. In a third study (study C), the comparability of the bioavailabilities of two oral and one intravenous levofloxacin formulations were investigated with 24 healthy male subjects in an open-label, randomized, three-way crossover study. Levofloxacin at 500 mg as a single tablet or an intravenous infusion was administered on day 1; following a 1-week washout period, subjects received the second regimen (i.e., the other oral formulation or the intravenous infusion); the third and final regimen was administered following a 1-week washout period. The concentrations of drug in plasma and urine were measured by validated high-pressure liquid chromatography methods. Pharmacokinetic parameters were estimated by noncompartmental methods. In both study A (oral levofloxacin) and study B (intravenous levofloxacin), steady state was attained within 48 h after the start of the multiple dosing on day 4. Levofloxacin pharmacokinetics were linear and predictable for the single and multiple 500-mg, once-daily oral and intravenous dosing regimens, and the values of the pharmacokinetic parameters for the oral and intravenous administrations were similar. Study C indicated that levofloxacin was rapidly and completely absorbed from the oral tablets, with mean times to the maximum concentration of drug in serum of approximately 1.5 h and mean absolute bioavailability of > or =99%. These results support the interchangeability of the oral and intravenous routes of levofloxacin administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.